Research programme: voltage-gated potassium channels - Correvio Pharma

Drug Profile

Research programme: voltage-gated potassium channels - Correvio Pharma

Alternative Names: Kv 1.5 channel blockers - Cardiome; Voltage-gated potassium channels research programme - Correvio Pharma

Latest Information Update: 21 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardiome Pharma
  • Class
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 15 May 2018 Cardiome Pharma is now called Correvio Pharma
  • 14 Sep 2004 Discontinued - Preclinical for Arrhythmias in Canada (unspecified route)
  • 26 Sep 2001 This programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top